Global BRICS Diabetes Treatment And Prevention Market Size, Share, Forecast Report, 2020-2027

Diabetes is a chronic disease characterized by elevated levels of blood glucose which leads to serious damage to the heart, eyes, kidneys, blood vessels and nerves. The most common of diabetes is type 2 diabetes which occurs when the body becomes resistant to insulin or doesn't make enough insulin. In the past three decades the prevalence of type 2 diabetes has risen dramatically in countries of all income levels. Type 1 diabetes, once known as juvenile diabetes or insulin-dependent diabetes, is a chronic condition in which the pancreas produces little or no insulin by itself. The market of diabetes treatment and prevention is increasing due to an increase in the prevalence of diabetes, changing lifestyle and increasing use of insulin for the treatment of diabetes. Increase awareness regarding prevention and treatment of diabetes favor the growth of this market. BRICS market of diabetes treatment and prevention is expected to reach USD 9.45 billion in 2023 from USD 3.53 billion in 2016 with a CAGR of approximately 11.52% during the forecast period 2017-2023.
Key Players:
Abbott Laboratories (U.S), Bayer AG (Germany), Eli Lily & Company (U.S), Medtronic (U.S), AstraZeneca Plc. (U.K), Lifescan (U.S), Terumo Medical Corporation (Japan) and Roche Holding AG (Switzerland).

Segmentation
BRICS diabetes treatment and prevention market has been segmented on the basis of type of diabetes which includes type 1 diabetes, type 2 diabetes and gestational diabetes. On the basis of treatment the market is segmented into medication, gene therapy, other methods of treatment and devices include Blood Glucose Meters and Strips, Continuous Glucose Monitors (CGMs), Injection Pens, Insulin Pump, others. On the basis of end users the market is segmented into hospitals, clinics, pharmaceutical companies and other end users.